Medical Journal of Australia 1982-11-27

Mebhydrolin napadisylate. A possible cause of reversible agranulocytosis and neutropenia.

J McEwen, W J Strickland

Index: Med. J. Aust. 2(11) , 523-5, (1982)

Full Text: HTML

Abstract

Mebhydrolin napadisylate is an antihistamine marketed in Australia as Fabahistin, and as an ingredient of Fabahistin Plus. Since June, 1973, 11 Australian reports associating this drug with either agranulocytosis or neutropenia have been received by the Adverse Drug Reactions Advisory Committee. In seven of these reports, mebhydrolin napadisylate was the only suspected drug. These reactions are probably uncommon, but the association should be borne in mind if evidence of agranulocytosis or neutropenia is found in patients taking the drug.

Related Compounds

  • Mebhydrolin napadi...

Related Articles:

Three explorative studies on the efficacy of the antihistamine mebhydroline (Omeril).

1995-07-01

[Int. J. Clin. Pharmacol. Ther. 33 , 373, (1995)]

Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan.

2008-07-01

[Gastroenterology 135(1) , 111-21, (2008)]

[Agranulocytosis associated with mebhydrolin napadisylate (Incidal)].

1984-03-01

[Harefuah 106(5) , 208-9, (1984)]

[Effect of antihistaminic preparations on gastric secretion in rats].

1983-05-01

[Biull. Eksp. Biol. Med. 95(5) , 44-6, (1983)]

[Methods for detecting diazoline in chemicotoxicological studies].

1991-01-01

[Sud. Med. Ekspert. 34(4) , 46-8, (1991)]

More Articles...